Literature DB >> 15127371

Antibiotic resistance in Streptococcus pneumoniae: what does the future hold?

Eric L Nuermberger1, William R Bishai.   

Abstract

The recent emergence of strains of drug-resistant Streptococcus pneumoniae (DRSP) is a serious clinical and public health problem. Several interventions have been proposed to limit the further emergence and spread of DRSP, including campaigns for appropriate antibiotic use and the introduction of pneumococcal conjugate vaccines. Whether the current epidemic of drug resistance in S. pneumoniae is sustainable or will succumb to current efforts to limit its spread will be decided by an interaction of factors related to the pathogen (i.e., the relative fitness of the resistant strains), to the prescription of antibiotic treatment (i.e., changes in selection pressure), and to the host (i.e., the ability to slow the transmission of DRSP). Much investigation is still needed to better ascertain how maintenance of DRSP strains in the community at large is influenced by each factor and affected by current interventions that are based on these factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15127371     DOI: 10.1086/382696

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Authors:  Kevin Fabrizio; Abraham Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

2.  Intrinsic epidemicity of Streptococcus pneumoniae depends on strain serotype and antibiotic susceptibility pattern.

Authors:  Matthieu Domenech de Cellès; Lulla Opatowski; Jérôme Salomon; Emmanuelle Varon; Claude Carbon; Pierre-Yves Boëlle; Didier Guillemot
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

Review 3.  Antimicrobial resistance determinants and future control.

Authors:  Stephan Harbarth; Matthew H Samore
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

4.  Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae.

Authors:  Crystal N Johnson; David E Briles; William H Benjamin; Susan K Hollingshead; Ken B Waites
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

5.  Antibody Treatment against Angiopoietin-Like 4 Reduces Pulmonary Edema and Injury in Secondary Pneumococcal Pneumonia.

Authors:  Liang Li; Benjamin Jie Wei Foo; Ka Wai Kwok; Noriho Sakamoto; Hiroshi Mukae; Koichi Izumikawa; Stéphane Mandard; Jean-Pierre Quenot; Laurent Lagrost; Wooi Keong Teh; Gurjeet Singh Kohli; Pengcheng Zhu; Hyungwon Choi; Martin Lindsay Buist; Ju Ee Seet; Liang Yang; Fang He; Vincent Tak Kwong Chow; Nguan Soon Tan
Journal:  mBio       Date:  2019-06-04       Impact factor: 7.867

6.  Knowledge, practices and attitudes on antibiotics use in Cameroon: Self-medication and prescription survey among children, adolescents and adults in private pharmacies.

Authors:  Grace-Ange Elong Ekambi; Cécile Okalla Ebongue; Ida Calixte Penda; Emmanuel Nnanga Nga; Emmanuel Mpondo Mpondo; Carole Else Eboumbou Moukoko
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

7.  Beta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamics.

Authors:  David Sevillano; Lorenzo Aguilar; Luis Alou; María-José Giménez; Natalia González; Martha Torrico; Fabio Cafini; Pilar Coronel; José Prieto
Journal:  PLoS One       Date:  2008-12-04       Impact factor: 3.240

8.  Spir2; a novel QTL on chromosome 4 contributes to susceptibility to pneumococcal infection in mice.

Authors:  Laura Wisby; Vitor E Fernandes; Daniel R Neill; Aras Kadioglu; Peter W Andrew; Paul Denny
Journal:  BMC Genomics       Date:  2013-04-11       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.